FTD/S9/80EFS (07-09)
Approved for use through 07/51/2012 ONB 0851-9931
U.S. Fatent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Papergroti. Restuction Act of 1995, no corsons are required to respect to a patiential of information unless it portions a valid ONS control number REQUEST FOR CONTINUED EXAMINATION(RCE)TRANSMITTAL (Submitted Only via EFS-Web) Application Filing Docket Number Art 10559995 2007-08-07 LEA 36780 1619 Number Date (if applicable) Unit First Named Examiner VENKATA-RANGARAO KANIKANTI RAYMOND YEAGER inventor Name This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or giant application filed prior to June 8. 1995, or io any design application. The Instruction Sheet for this form is located at WWW.USPTO.GOV SUBMISSION REQUIRED UNDER 37 CFR 1.114 Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the profer in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s). Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this how is not checked Consider the arguments in the Appeal Brief or Reply Brief previously filed on (Other S Englosed X Amendment/Reply [X] Information Disclosure Statement (IDS) Afficiavit(s)/ Declaration(s) Other PETITION FOR EXTENSION OF TIME AND RESPONSE MISCELLANEOUS Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of months (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1,17(i) required) Other FFFS The RCE fee under 37 CFR 1,17(e) is required by 37 CFR 1,114 when the RCE is filled. The Director is hereby authorized to charge any underpayment of fees, or credit any overpayments, to

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

EFS - Web 2.1.15

Decosit Account No.

Patent Practitioner Signature
Applicant Signature

504260

PTO/SE/UDERS (07-08)

Approved for use through 07/31/2012 GMS 0651-2031

U.S. Pawerl and Trademark Officer, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respect of a following of information unless it contains a voted OMB control number.

Signature of Registered U.S. Patent Practitioner				
Signature	/JESSICA MONACHELLO/	Date (YYYY-MM-DD)	2011-02-03	
Name	JESSICA WONACHELLO	Registration Number	58015	

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to fife (and by the USPTC to processe) an application, Confidentiality is governed by \$5 U.S.C. 122 and \$57 CFR 1.11 and 1.14. This collection is estimated to lake 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTC. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form after suggestions for reducing his burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenark Office, U.S. Department of Commerce, P.O. Box 1496, Alwayandria, VA. 2313-1490.

if you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicities is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademerk Office is to process and/or examine your submission related to a patient application or patient. If you do not furnish requested information, the U.S. Patient and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patient.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information
 Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the
 Department of Justice to defermine whether the Freedom of Information Act requires disclosure of these records.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement nepotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need
 for the information in order to perform a contract. Recipients of information is half be required to comply with the
 requirements of the Privacy Act of 1974, as amended, oursuant to 5 U.S.C. 552a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c))
- 7. A record from this system of records may be disclosed, as a routline use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 30 L/S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 157. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filted in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application goes no build inspections or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.